Cargando…
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolerability an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381505/ https://www.ncbi.nlm.nih.gov/pubmed/34425850 http://dx.doi.org/10.1186/s13045-021-01140-z |
_version_ | 1783741382946455552 |
---|---|
author | Jiang, Bo Qi, Junyuan Song, Yuqin Li, Zengjun Tu, Meifeng Ping, Lingyan Liu, Zongliang Bao, Hanying Xu, Zusheng Qiu, Lugui |
author_facet | Jiang, Bo Qi, Junyuan Song, Yuqin Li, Zengjun Tu, Meifeng Ping, Lingyan Liu, Zongliang Bao, Hanying Xu, Zusheng Qiu, Lugui |
author_sort | Jiang, Bo |
collection | PubMed |
description | YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolerability and dose-limiting toxicity (DLT). The secondary outcomes were pharmacokinetic parameters, progression-free survival (PFS) and the objective response rate (ORR). Since no patients experienced DLT, the maximum tolerated dose (MTD) was not reached. The majority (≥ 5%) of drug-related adverse events were ≥ grade III, being neutropenia (44.0%), pneumonia (16.0%), hyperuricemia (12.0%), lymphocythemia (8.0%), leukopenia (8.0%) and pneumonitis (8.0%). The overall ORR was 64.0% (95% confidence interval (CI): 45.2, 82.8%) including 5 patients with complete remission (CR), 11 with partial remission (PR), 2 with stable disease (SD) and 7 with progressive disease (PD), while the disease control rate (DCR) was 72.0% (95% CI: 54.4, 89.6%). The ORR of 10 patients with follicular lymphoma was 90%. The median PFS time was 255 days. One PR patient with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received 40 mg q.d. had a durable response of around 36 months. The median PFS time of 10 patients with follicular lymphoma was 300 days. A recommended phase 2 dose of 80 mg q.d. was established. Considering that YY-20394 was well-tolerated with promising preliminary efficacy, further development is warranted. Trial registration clinicaltrials.gov, NCT03757000, retrospectively registered, November 28, 2018, https://clinicaltrials.gov/ct2/show/NCT03757000?term=NCT03757000&draw=2&rank=1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01140-z. |
format | Online Article Text |
id | pubmed-8381505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83815052021-08-23 Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies Jiang, Bo Qi, Junyuan Song, Yuqin Li, Zengjun Tu, Meifeng Ping, Lingyan Liu, Zongliang Bao, Hanying Xu, Zusheng Qiu, Lugui J Hematol Oncol Letter to the Editor YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolerability and dose-limiting toxicity (DLT). The secondary outcomes were pharmacokinetic parameters, progression-free survival (PFS) and the objective response rate (ORR). Since no patients experienced DLT, the maximum tolerated dose (MTD) was not reached. The majority (≥ 5%) of drug-related adverse events were ≥ grade III, being neutropenia (44.0%), pneumonia (16.0%), hyperuricemia (12.0%), lymphocythemia (8.0%), leukopenia (8.0%) and pneumonitis (8.0%). The overall ORR was 64.0% (95% confidence interval (CI): 45.2, 82.8%) including 5 patients with complete remission (CR), 11 with partial remission (PR), 2 with stable disease (SD) and 7 with progressive disease (PD), while the disease control rate (DCR) was 72.0% (95% CI: 54.4, 89.6%). The ORR of 10 patients with follicular lymphoma was 90%. The median PFS time was 255 days. One PR patient with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received 40 mg q.d. had a durable response of around 36 months. The median PFS time of 10 patients with follicular lymphoma was 300 days. A recommended phase 2 dose of 80 mg q.d. was established. Considering that YY-20394 was well-tolerated with promising preliminary efficacy, further development is warranted. Trial registration clinicaltrials.gov, NCT03757000, retrospectively registered, November 28, 2018, https://clinicaltrials.gov/ct2/show/NCT03757000?term=NCT03757000&draw=2&rank=1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01140-z. BioMed Central 2021-08-23 /pmc/articles/PMC8381505/ /pubmed/34425850 http://dx.doi.org/10.1186/s13045-021-01140-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Letter to the Editor Jiang, Bo Qi, Junyuan Song, Yuqin Li, Zengjun Tu, Meifeng Ping, Lingyan Liu, Zongliang Bao, Hanying Xu, Zusheng Qiu, Lugui Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title | Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title_full | Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title_fullStr | Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title_full_unstemmed | Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title_short | Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies |
title_sort | phase 1 clinical trial of the pi3kδ inhibitor yy-20394 in patients with b-cell hematological malignancies |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381505/ https://www.ncbi.nlm.nih.gov/pubmed/34425850 http://dx.doi.org/10.1186/s13045-021-01140-z |
work_keys_str_mv | AT jiangbo phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT qijunyuan phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT songyuqin phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT lizengjun phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT tumeifeng phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT pinglingyan phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT liuzongliang phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT baohanying phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT xuzusheng phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies AT qiulugui phase1clinicaltrialofthepi3kdinhibitoryy20394inpatientswithbcellhematologicalmalignancies |